Key facts
- Zenas BioPharma announced positive Phase 3 trial results for obexelimab.
- The trial data supports the potential efficacy of obexelimab in treating its target condition.
Zenas BioPharma has announced positive Phase 3 trial results for its drug candidate, obexelimab. The company stated that the data gathered from the trial supports the potential efficacy of obexelimab in treating its target condition. Further details on the specific condition and the trial's outcomes were not immediately available, but the announcement marks a significant step in the drug's development pipeline.